Romanian market continued to grow at double-figure rate in Q1 2019
…used for central nervous system disorders grew by 6% only. The order of the 3 leading corporations in terms of value has changed in Q1 2019 in the wake of the significant growth in medicines allocated to cost-volume-result contracts (for interferon free therapy for hepatitis C).
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)